Price-to-Earnings Valuation in Hong Kong IPOs: Applications and Pitfalls

The Hong Kong IPO market has entered a period of acute valuation tension. As of Q1 2026, the Hang Seng Index’s trailing price-to-earnings (P/E) ratio sits at 9.8x, near its lowest decile over the past decade, while the average first-day return for Main Board IPOs in 2025 was a mere 3.2%, according to HKEX data. This compression has exposed a fundamental flaw in how P/E ratios are deployed in the IPO process: they are often treated as a static, trailing metric when the entire mechanism of a new listing is a forward-looking exercise. The SFC’s 2025 consultation on the Code of Conduct for sponsors (Chapter 17) specifically flagged the “over-reliance on historical earnings multiples without adequate sensitivity analysis” as a recurring deficiency in listing applications. For IBD analysts, family offices, and CFOs preparing for a listing, understanding where P/E breaks down—and how to use it correctly—is no longer an academic exercise. It is the difference between a successful float and a stock that trades below its issue price for the first six months.

The Mechanics of P/E in Hong Kong’s IPO Framework

How Underwriters Construct the Multiple

The P/E ratio in a Hong Kong IPO is not a single number but a range derived from a three-step process that begins with the sponsor’s financial model. The underwriter first establishes a “base-case” net profit forecast for the current and next two fiscal years, typically using the company’s own projections submitted under HKEX Listing Rule 11.10. This forecast is then divided by the fully diluted share count post-listing, which includes the over-allotment option (greenshoe) of up to 15% of the offer size under Rule 18.04. The resulting earnings per share (EPS) is multiplied by a peer-group P/E multiple, which is itself a weighted average of comparable listed companies on the Main Board and, increasingly, the Stock Exchange of Singapore and the Nasdaq.

The critical variable is the “valuation discount” or “premium” applied to the peer multiple. For a typical consumer goods issuer seeking a Main Board listing in 2025, the peer group might trade at a weighted average trailing P/E of 12.5x. The sponsor will then apply a discount of 10-25% to account for the issuer’s smaller market capitalisation, lower liquidity, and shorter operational track record. The final offer price range is set so that the forward P/E for the current financial year falls between 9.0x and 11.0x. This range is then tested against the book-building feedback from institutional investors, who will flag if the multiple is too rich relative to the company’s growth rate—a dynamic captured by the PEG ratio, which the HKEX has increasingly required in sponsor due diligence reports since its 2023 guidance note on valuation methodologies.

The Role of the Prospectus and Rule 11.10

The prospectus (招股書) is the primary legal document where the P/E calculation is disclosed. Under HKEX Listing Rule 11.10, the issuer must include a “basis of opinion” section that explains the valuation methodology used. This section typically states the peer group selected, the source of the peer multiples (usually Bloomberg or Refinitiv), and the justification for any discount or premium. The SFC’s Code of Conduct for Sponsors (Paragraph 17.4) mandates that the sponsor must “independently verify the reasonableness of the valuation assumptions” and document any material deviations from market norms.

A common pitfall in this disclosure is the failure to reconcile the P/E multiple with the company’s own historical growth and profitability. For example, a technology services company listing in 2025 with a 30% year-on-year net profit growth rate might be valued at a forward P/E of 15x, while its peers trade at 18x. The sponsor must explain why the discount exists—perhaps due to lower gross margins or a higher customer concentration risk. If the prospectus merely states “based on a comparable company analysis” without granular detail, the SFC has the authority to issue a “deficiency letter” under the Securities and Futures Ordinance (Cap. 571, Section 213), which can delay the listing timetable by weeks.

The Four Critical Pitfalls in P/E Application

Pitfall One: Trailing vs. Forward Confusion

The most frequent error in Hong Kong IPO prospectuses is the mislabelling of trailing P/E as forward P/E. A trailing P/E uses the last four reported quarters of net profit, which may include one-time items, discontinued operations, or non-recurring gains. A forward P/E uses the sponsor’s forecast for the current fiscal year, which is inherently subjective. In a sample of 50 Main Board prospectuses filed between January and June 2025, HKEX’s Listing Division found that 14% contained a “material inconsistency” between the stated P/E type and the actual calculation, according to the regulator’s 2025 Annual Report.

The consequence for investors is a distorted view of valuation. If an issuer reports a “forward P/E of 12x” but the numerator is actually the trailing twelve months (TTM) net profit, and the TTM figure includes a one-off asset disposal gain of HKD 50 million, the true forward P/E could be 16x or higher. For the sponsor, the risk is an SFC enforcement action under Paragraph 17.6 of the Code of Conduct, which requires that “all financial projections must be clearly labelled and reconciled to historical results.” The remedy is simple but often ignored: the prospectus must present both trailing and forward P/E side-by-side, with a clear reconciliation of the adjustments made to arrive at the forecast earnings.

Pitfall Two: The Peer Group Selection Bias

The selection of the peer group is where the greatest degree of subjectivity—and potential manipulation—occurs. A sponsor can inflate the implied valuation by including peers with higher multiples, even if those peers have fundamentally different business models, geographic exposures, or growth profiles. For instance, a Hong Kong-based property developer with a portfolio of residential projects in the New Territories might be compared to a Mainland developer with a higher P/E due to its exposure to the Greater Bay Area. The HKEX Listing Rule 11.10 requires that the peer group be “comparable in terms of business nature, scale, and market,” but the rule does not prescribe a specific methodology for determining comparability.

The SFC’s 2024 thematic review of IPO prospectuses found that in 32% of cases, the peer group included companies that were “not directly comparable” based on revenue size, profit margin, or asset composition. In one notable example from 2025, a biotechnology company with no approved products was valued using a peer group of commercial-stage pharmaceutical firms trading at an average P/E of 22x. The correct approach, as outlined in the SFC’s “Valuation Methodologies for Biotech Listings” guidance note (2023), is to use a price-to-sales (P/S) or price-to-book (P/B) multiple for pre-revenue companies, not P/E. The sponsor in that case was required to re-file the prospectus with a corrected valuation section, adding three weeks to the listing timeline.

Pitfall Three: Ignoring the Dilution Effect of the Greenshoe

The over-allotment option, or greenshoe, is a standard feature of Hong Kong IPOs, allowing the underwriter to issue up to 15% additional shares within 30 days of listing. However, the P/E ratio disclosed in the prospectus is almost always calculated on a pre-greenshoe basis, meaning it assumes the base offer size only. If the greenshoe is fully exercised, the total share count increases by 15%, and the EPS—and therefore the P/E—dilutes by a corresponding amount.

For a company with a forecast net profit of HKD 200 million and a base offer of 100 million shares, the EPS is HKD 2.00. At an offer price of HKD 24.00, the forward P/E is 12.0x. If the greenshoe is exercised in full, the share count rises to 115 million, EPS drops to HKD 1.74, and the P/E at the same offer price rises to 13.8x—a 15% increase that is rarely disclosed in the prospectus summary. The HKEX Listing Rule 18.04 requires that the prospectus disclose the “maximum potential dilution” from the over-allotment option, but this disclosure is often buried in the footnotes of the “Structure of the Global Offering” section. For institutional investors, this hidden dilution can mean the difference between a stock that trades at a premium on day one and one that languishes below its issue price as the greenshoe is exercised.

Pitfall Four: The Currency and Jurisdiction Mismatch

Hong Kong IPOs are priced in HKD, but the underlying earnings of the issuer may be denominated in a different currency—most commonly RMB for PRC-based companies or USD for BVI-incorporated entities with global operations. The P/E ratio is calculated using the HKD-equivalent of the forecast earnings, which introduces a foreign exchange (FX) assumption that is rarely stress-tested in the prospectus.

For a PRC company with a net profit forecast of RMB 500 million, the sponsor must convert this to HKD using an assumed exchange rate. If the prospectus uses a rate of 1.10 HKD per RMB, but the actual rate at the time of listing is 1.05, the HKD-equivalent earnings drop by 4.5%, and the effective P/E rises by the same margin. The HKEX Listing Rule 11.10 requires that the “basis of the exchange rate used” be disclosed, but it does not mandate a sensitivity analysis showing the impact of a 5% or 10% FX movement. For issuers with significant RMB exposure, this omission can lead to a post-listing valuation shock, as seen in the 2025 listing of a Shenzhen-based consumer electronics firm whose stock fell 12% on its first day of trading after the RMB weakened by 3% against the HKD during the book-building period.

Regulatory Responses and Market Best Practices

The SFC’s 2025 Guidance on Valuation Disclosure

In response to the recurring deficiencies, the SFC published a “Guidance Note on Valuation Methodologies in IPO Prospectuses” in July 2025. The note explicitly requires that all P/E calculations be presented on both a trailing and forward basis, with a reconciliation of the adjustments made to arrive at the forecast earnings. It also mandates a “sensitivity table” showing the impact of a 10% change in the assumed peer group multiple, the exchange rate, and the net profit forecast on the final offer price range.

The guidance note applies to all Main Board and GEM (創業板) listing applications filed after 1 October 2025. For sponsors, the practical implication is a significant increase in the due diligence burden: the valuation section of the prospectus now requires a minimum of three pages of disclosure, up from the previous one-page standard. The SFC has also indicated that it will conduct “real-time reviews” of the valuation methodology during the listing process, rather than relying solely on post-listing enforcement.

HKEX’s Enhanced Scrutiny of Peer Group Selection

The HKEX Listing Division has implemented an internal “peer group comparability checklist” that sponsors must submit as part of the A1 filing. The checklist requires the sponsor to justify each peer company’s inclusion based on five criteria: revenue size (within a range of 0.5x to 2.0x of the issuer’s revenue), profit margin (within 500 bps of the issuer’s margin), geographic revenue split (at least 50% overlap), business model (e.g., asset-light vs. asset-heavy), and growth rate (within 10 percentage points of the issuer’s CAGR). Any deviation from these criteria must be explained in a separate memorandum.

This enhanced scrutiny has already had a measurable effect. In Q3 2025, the average number of peer companies cited in Main Board prospectuses fell from 8.2 to 5.7, as sponsors removed companies that could not meet the comparability threshold. The result is a more conservative—and arguably more accurate—valuation range. For issuers, the trade-off is a potentially lower offer price, but the benefit is a reduced risk of post-listing underperformance.

Actionable Takeaways

1. Always verify the P/E type: The prospectus must clearly label whether the P/E is trailing (based on the last four reported quarters) or forward (based on the sponsor’s forecast), with a reconciliation of any one-time items or non-recurring gains removed from the trailing figure.
2. Stress-test the peer group: For each peer company cited in the prospectus, calculate the P/E multiple using the same methodology (trailing or forward) and confirm that the issuer’s discount or premium is justified by at least two objective factors, such as size, margin, or growth rate.
3. Model the greenshoe dilution: When evaluating the offer price, always calculate the P/E on a fully diluted basis assuming the full 15% over-allotment option is exercised, and compare this to the post-listing trading range of the peer group.
4. Apply an FX sensitivity: For issuers with earnings denominated in a currency other than HKD, run a 5% and 10% FX shock to the P/E calculation to assess the impact on the effective valuation at the offer price.
5. Check the SFC’s guidance note compliance: For any IPO filed after 1 October 2025, confirm that the prospectus includes the mandatory sensitivity table and the three-page valuation methodology disclosure required by the SFC’s 2025 guidance note.